UCB SA And Immunomedics, Inc. Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus

Published: Jun 16, 2010

ROME, June 16, 2010 (GLOBE NEWSWIRE) -- UCB (EURONEXT:UCB) and Immunomedics Inc. (Nasdaq:IMMU) announced new lupus drug candidate, epratuzumab, provided a significant reduction in disease activity in patients with moderate to severe active systemic lupus erythematosus (SLE). Data presented at the European League Against Rheumatism (EULAR) meeting in Rome from the phase IIb study, EMBLEMâ„¢, showed the clinical efficacy of epratuzumab in patients with SLE.

Back to news